Recruiting
Early Phase 1

OUD+ALC

Sponsor:

Ohio State University

Code:

NCT07894276

Conditions

Opioid Use Disorder

Alcohol Intoxication

Pain

Eligibility Criteria

Sex: All

Age: 21 - 65

Healthy Volunteers: Not accepted

Interventions

Alcohol

Placebo

Study Details

Brief summary:

The goal of this clinical trial is to examine whether individuals with co-occurring opioid use disorder and alcohol use (OUD+ALC) experience heightened pain sensitivity, pain-related negative affect, and greater alcohol reinforcement compared with alcohol-only (ALC) or opioid-only (OUD-ALC) users.

The main questions it aims to answer are:

  • Aim 1. Do individuals with OUD+ALC experience increased pain and pain-related negative affect during periods of sobriety relative to mono-users of alcohol (ALC only) and opioids (OUD-ALC)?
  • Aim 2. Do individuals with OUD+ALC experience greater alcohol-induced analgesia and alcohol reinforcement compared with mono-users of alcohol (ALC only) and opioids (OUD-ALC)?

Participants will:

  • Complete a screening session
  • Complete one lab session including a comprehensive assessment battery involving multimodal assessments of pain during sobriety
  • Complete two experimental lab sessions that will include intravenous (IV) administration of either 80mg% alcohol or placebo (saline), order counterbalanced, to measure alcohol's acute effects on pain and pain-related negative affect

Conditions

Opioid Use Disorder

Alcohol Intoxication

Pain

Study ID

NCT07894276

Start date

Nov 12, 2026

Status verified date

Nov, 2026

Completion date

Aug, 2028

Anticipated

Primary completion date

Aug, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

ALC Only Group:

  • 21-65 years old
  • Required to meet NIAAA criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week)

OUD + ALC Group:

  • 21-65 years old
  • Required to meet NIAAA criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week)
  • Meet DSM-5 criteria for current opioid use disorder (OUD)
  • Report using recreational opioids at least weekly (past month)

OUD-ALC Group:

  • 21-65 years old
  • Meet DSM-5 criteria for current OUD
  • Report using recreational opioids at least weekly (past month)
  • Meet "light drinking" criteria (consuming equal to or less than 4 drinks per week for women or consuming equal to or less than 5 drinks per week for men)
  • Report at least 1 but no more than 3 binge episodes over the past 12 months

Exclusion Criteria:

  • Serious medical problems
  • Current medical or psychiatric conditions requiring medication for which alcohol is contraindicated (including prescription opioids)
  • Any serious medical problems
  • Sensitivity or allergy to alcohol
  • Body weight < 110 or > 210 lbs for alcohol administration
  • Injury, trauma, nerve/tissue damage, or deformity prohibiting sensory testing
  • Moderate to severe substance use disorders other than alcohol use disorder (AUD) or OUD
  • Current severe mental illness, including mania or psychosis
  • Currently seeking inpatient/intensive treatment for addictive behaviors
  • Pregnant or nursing and unwilling to take measures to avoid becoming pregnant during the study (females)
  • Chronic pain requiring ongoing pain management within the past three months.
  • Clinically significant alcohol or opioid withdrawal symptoms the day of the lab sessions, defined as a score >10 on the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar) or a score >12 on the Clinical Opioid Withdrawal Scale (COWS)
  • Positive alcohol breath test or opioid urine screen the day of the experimental lab sessions to avoid the potential for alcohol-opioid interactions.
  • Smoking more than 6 cigarettes per day (or alternative form equivalent)
  • Not fluent in English

Study Design

Enrollment

90 participants

Anticipated

Allocation

Non randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

other: Alcohol (ALC) Only Group

Participants in this group will be required to meet the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week).

other: Opioid Use Disorder (OUD) + ALC Group

Participants in this group will be required to 1) Meet the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week); 2) Meet DSM-5 criteria for current OUD and; 3) Report using recreational opioids at least weekly (past month).

other: OUD-ALC Group

Participants in this group will be required to 1) Meet DSM-5 criteria for current OUD; 2) Report using recreational opioids at least weekly (past month); 3) Meet "light drinking" criteria (consuming less than or equal to 4 alcoholic drinks per week (female) or less than or equal to 5 alcoholic drinks (men) and; 4) Report at least 1 but no more than 3 binge episodes over the past 12 months.

Interventions

Alcohol

Participants will receive 80 mg% intravenous alcohol and saline.

Placebo

Participants receive placebo (saline) intravenously.

Primary outcome measure

  • Pain intensity during the pressure task, measured using a visual analog scale (VAS) [ Time Frame: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3) ]
  • Pain pressure threshold during the pressure task [ Time Frame: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3) ]
  • Startle eyeblink potentiation during the anticipation task [ Time Frame: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3) ]
  • Self-reported affect during the anticipation task [ Time Frame: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3) ]
  • Subjective affective response to alcohol in the lab [ Time Frame: Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart. ]

Central Contacts and Locations

Central contacts

Locations

Ohio State University

Recruiting

Columbus, Ohio, United States, 43210

Contacts

More Information

Sponsor

Ohio State University

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • Intravenous alcohol administration
  • Opioid Use Disorder

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Ohio State University on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.